Evaluating Adherence to Highly Active Antiretroviral Therapy with Use of Pill Counts and Viral Load Measurement in the Drug Resources Enhancement against AIDS and Malnutrition Program in Mozambique
Community of Sant'Egidio, Drug Resources Enhancement against AIDS and Malnutrition Program, Rome, Italy. Clinical Infectious Diseases
(Impact Factor: 8.89).
05/2008; 46(10):1609-16. DOI: 10.1086/587659
Maintaining treatment adherence among the growing number of patients receiving antiretroviral treatment in Africa is a dramatic challenge. The objective of our study was to explore the results of a computerized pill count method and to test the validity, sensitivity, and specificity of this method with respect to viral load measurement in an African setting.
We performed a prospective, observational study involving patients who received first-line highly active antiretroviral therapy in Mozambique from 1 April 2005 through 31 March 2006. Enrolled patients had received treatment for at least 3 months before the study. For defining treatment adherence levels, pill counts were used, and the results were analyzed with viral load measurements at the end of the observation period.
The study involved 531 participants. During the 12 months of observation, 137 patients left the program or discontinued first-line therapy. Of the remaining 394 patients, 284 (72.1%) had >95% treatment adherence; of those 284 patients, 274 (96.5%) had a final viral load <1000 copies/mL. A Cox proportional hazards analysis revealed that the relationship between >95% treatment adherence and the final viral load was closer than that between >90% treatment adherence and viral load.
Treatment adherence >95% maximizes the results of the nonnucleoside reverse-transcriptase inhibitor-based regimen. The pill count method appears to be a reliable and economic tool for monitoring treatment adherence in resource-limited settings.
Available from: Mary Bachman DeSilva
- "Recent evidence suggests that non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens may be more forgiving of minor deviations in adherence (Bangsberg 2006). Nevertheless, the essential relationship between adherence and UDVL remains: superb adherence to NNRTIs is rewarded by the highest rates of virologic success (Nachega et al. 2007; San Lio et al. 2008). A core question in the NNRTI/adherence debate is whether the commonly accepted definition of 'optimal adherence' based around the C95% threshold is appropriately strict, or overly strict. "
[Show abstract] [Hide abstract]
ABSTRACT: Little is known about the importance of dose timing to successful antiretroviral therapy (ART). In a cohort comprised of Chinese
HIV/AIDS patients, we measured adherence among subjects for 6months using three methods in parallel: self-report using a
visual analog scale (SR-VAS), pill count, and electronic drug monitors (EDM). We calculated two adherence metrics using the
EDM data. The first metric used the proportion of doses taken; the second metric credited doses as adherent only if taken
within a 1-h window of a pre-specified dose time (EDM ‘proportion taken within dose time’). Of the adherence measures, EDM
had the strongest associations with viral suppression. Of the two EDM metrics, incorporating dose timing had a stronger association
with viral suppression. We conclude that dose timing is also an important determinant of successful ART, and should be considered
as an additional dimension to overall adherence.
KeywordsHIV/AIDS-Antiretroviral therapy-Adherence-Dose timing-China-Non nucleoside reverse transcriptase inhibitor
AIDS and Behavior 08/2010; 14(4):785-793. DOI:10.1007/s10461-009-9555-9 · 3.49 Impact Factor
Available from: David Bangsberg
- "email@example.com 2003; Landman et al. 2003; Laniece et al. 2003; Laurent et al. 2004; Laurent et al. 2005a, b; Mills et al. 2006b; Nachega et al. 2004; Orrell et al. 2003; Oyugi et al. 2004; Remien et al. 2003; San Lio et al. 2008; Tadios and Davey 2006; Weidle et al. 2002; Weidle et al. 2006; Weiser et al. 2003) there has been little discussion about how HIV? women balance the demands of adherence to HIV ART, childcare, and antiretroviral adherence among their children who are HIV-infected. Motherhood potentially places particular stress on HIV-infected women due to higher levels of depression, poorer family cohesion, less ability to perform daily functions, and the need to care for HIV-infected children (Murphy et al. 2002). "
[Show abstract] [Hide abstract]
ABSTRACT: We conducted a study to assess the effect of family-based treatment on adherence amongst HIV-infected parents and their HIV-infected children attending the Mother-To-Child-Transmission Plus program in Kampala, Uganda. Adherence was assessed using home-based pill counts and self-report. Mean adherence was over 94%. Depression was associated with incomplete adherence on multivariable analysis. Adherence declined over time. Qualitative interviews revealed lack of transportation money, stigma, clinical response to therapy, drug packaging, and cost of therapy may impact adherence. Our results indicate that providing ART to all eligible HIV-infected members in a household is associated with excellent adherence in both parents and children. Adherence to ART among new parents declines over time, even when patients receive treatment at no cost. Depression should be addressed as a potential barrier to adherence. Further study is necessary to assess the long-term impact of this family treatment model on adherence to ART in resource-limited settings.
AIDS and Behavior 04/2009; 13 Suppl 1(S1):82-91. DOI:10.1007/s10461-009-9546-x · 3.49 Impact Factor
Available from: Andy I M Hoepelman
[Show abstract] [Hide abstract]
ABSTRACT: The purpose of this study was to assess the one-year efficacy of highly active antiretroviral therapy (HAART) administered by general practitioners in a primary care community clinic in rural South Africa. We performed an observational cohort study of 675 treatment-naive human immunodeficiency virus (HIV)-infected patients (including 66 children) who began HAART at least 12 months prior to the data analyses. Throughout treatment, the CD4+ T-cell count (percentage of CD4+ T-cells in children) and plasma HIV-RNA level were determined and the patient's weight was recorded. The primary outcome was mortality. Secondary outcomes were viral suppression, immunological response, and weight gain. One year after the start of HAART, 100 of the 675 (15%) patients were lost to follow-up and 119 patients (18%), including six children, died. Mortality was highest during the first few months of treatment. Based on an on-treatment analysis at one year after the start of therapy, 83% of adults and 71% of children had a viral load <400 copies/ml; the viral load was <50 copies/ml in 70% of adults and 61% of children. At one year, the mean CD4+ T-cell count in adults had increased by 236/mm(3), and the mean body mass index (BMI) had increased by 3.5 kg/m(2). In children, the mean CD4% had increased by 17.6. A low Karnofsky score and a low baseline CD4+ T-cell count were independently associated with death. In addition to these factors, a low baseline BMI and gender were predictive of a poor immunological outcome. Our study shows that adequately monitored HIV/acquired immunodeficiency syndrome (AIDS) care administered by general practitioners and their staff is feasible and leads to good results in a rural, primary care center in sub-Saharan Africa. In order to achieve even better results, early mortality should be reduced and efforts should be made to start HAART earlier.
European Journal of Clinical Microbiology 10/2008; 27(10):977-84. DOI:10.1007/s10096-008-0534-2 · 2.67 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.